Descripción de la Presentación: Tamizaje Suplementario Para la Detección de Cáncer de Seno
Aproximadamente el 40% de las mujeres mayores de 40 años de edad tienen senos densos (1). El tejido denso reduce la efectividad de la mamografía y aumenta el riesgo de desarrollar cáncer de seno. Las mujeres con senos densos están a un mayor riesgo de padecer de cánceres de intervalo con un mayor estadío (2). Al añadir el tamizaje suplementario a la mamografía debemos detectar el cáncer de seno más temprano que de otra manera sería detectado clínicamente como una masa palpable. En esta presentación discutiremos tamizaje suplementario para la detección de cáncer de seno incluyendo: tomosíntesis, ecografía, resonancia magnética, imágenes moleculares de seno y mamografía de contraste. Referencias: 1. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014;106(10):10.1093/jnci/dju255. Print 2014 Oct. 2. Arora N, King TA, Jacks LM, et al. Impact of breast density on the presenting features of malignancy. Ann Surg Oncol 2010;17 Suppl 3:211-218.
Approximately 40% of women over 40 years of age have dense breasts (1). Dense tissue reduces the effectiveness of mammography and increases the risk of developing breast cancer. Women with dense breasts are at increased risk for higher stage interval cancers (2). By adding supplemental screening to mammography, we should detect breast cancer earlier than would otherwise be detected clinically as a palpable mass. In this presentation, we will discuss supplemental screening for breast cancer detection, including tomosynthesis, ultrasound, magnetic resonance imaging, molecular breast imaging, and contrast mammography. References: 1. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014;106(10):10.1093/jnci/dju255. Print 2014 Oct. 2. Arora N, King TA, Jacks LM, et al. Impact of breast density on the presenting features of malignancy. Ann Surg Oncol 2010;17 Suppl 3:211-218.
CME Information
Earn up to 1 AMA PRA Category 1 CreditTM
Physicians Amedco LLC designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM for physicians. Physiciansshould claim only the credit commensurate with the extent of their participation in the activity.
Learner Notice
Acknowledgement of Financial Commercial Support- No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, and complete an evaluation survey to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Breast Imaging . Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Professions in scope for this activity are listed below. Amedco Joint Accreditation Provider Number: 4008163
Physicians- Amedco LLC designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
| Name | Commercial Interest- Relationship |
| Dana Ataya | NA |
| Yara Feliciano | NA |
| Nuria Gramkee | NA |
| Ryan Dixon | NA |
- Develop mechanisms to efficiently implement supplemental screening algorithms in the breast imaging practice.
- Discuss modality-specific acquisition protocol, logistics and workflow for screening and/or supplemental screening indications.
- Describe existing data regarding the strengths and weaknesses of mammography, digital breast tomosynthesis (DBT), ultrasound, contrast-enhanced mammography and MRI for screening and/or supplemental screening indications.
